The vitamin B12 levels of cerebrospinal fluid were assayed microbiologically (Lactobacillus leichmannii method) using samples from 44 patients with various neurological disorders, 4 patients with megalo blastic anemia and 34 controls. Twenty-seven controls that did not receive vitamin B12 showed a mean cerebrospinal fluid vitamin B12 level of 21.5pg/ml (range: 0-60). No decrease in cerebrospinal fluid vitamin B12 level was seen in patients with subacute myelo-optico-neuropathy (SMON). High levels of cerebrospinal fluid vitamin B12 were observed only in the patients receiving long term administration of the vitamin. Intrathecal administration of vitamin B12 caused only a slight increase in serum vitamin B12 level after four hours. The existence of a blood brain barrier for vitamin B12 was suggested.
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Summary
The vitamin B12 levels of cerebrospinal fluid were assayed microbiologically (Lactobacillus leichmannii method) using samples from 44 patients with various neurological disorders, 4 patients with megalo blastic anemia and 34 controls. Twenty-seven controls that did not receive vitamin B12 showed a mean cerebrospinal fluid vitamin B12 level of 21.5pg/ml (range: 0-60). No decrease in cerebrospinal fluid vitamin B12 level was seen in patients with subacute myelo-optico-neuropathy (SMON). High levels of cerebrospinal fluid vitamin B12 were observed only in the patients receiving long term administration of the vitamin. Intrathecal administration of vitamin B12 caused only a slight increase in serum vitamin B12 level after four hours. The existence of a blood brain barrier for vitamin B12 was suggested.
The role of vitamin B12 (B12) in the central nervous system has not yet been fully elucidated. Subacute combined degeneration of the cord (SACD) in per nicious anemia is the only occasion in which B12 is associated with the cause of neurological symptoms (1) . Subacute myelo-optico-neuropathy (SMON) (2 , 3) have been attracting attention since early reports because of the similarity of the clinical features with those of SACD (4). Many attempts to treat SMON with B12 resulted in failure and no decrease of serum B12 levels have been reported in SMON (5) . Nevertheless, UKYO (6) reported that intrathecal B12 administration produced some improvement in neurological manifestations in SMON. Al though many papers have reported B12 levels in cerebrospinal fluid (CSF) (7) (8) (9) (10) (11) (12) (13) (14) , little is known about the transport of B12 from the blood to the CSF (15) and vice versa (6, 16) . The purposes of this paper are to report CSF B12 levels in various neurological diseases especially in SMON and to see whether blood B12 is easily transported to and from the CSF.
MATERIALS AND METHODS
Serum and CSF B12 levels were assayed microbiologically using Lactobacillus leichmannii as a test organism (17) . Three to 5ml of CSF was used for KCN extraction and the final volume was adjusted to 10ml instead of 25ml for blood B12 assay. This diminution of dilution rate enabled CSF B12 levels to be assayed in the same range of standard curve as those of blood. CSF B12 levels were assayed for 34 controls and 44 patients with various neurological disorders, including 23 cases of SMON as listed in Table 1 . Controls were subjects with no neurological Table 1 . Patients studied.
diseases. The CSF was taken when spinal puncture was performed to exclude any cerebral and spinal disorder. Three patients with folic acid deficiency and 1 patient with pernicious anemia were also studied. Effects of a single injection of B12 on CSF levels of the vitamin were studied in two patients. Change of serum B12 levels after intrathecal injection of B12 was examined in a typical case of a SMON patient who had not received B12 previously. Figure 1 shows the CSF B12 levels in patients with various neurological diseases and the controls. No disease specific feature was seen in CSF B12 levels. High Table 3 , no increase of CSF B12 levels was observed in either patients 1 and 3 days after the injection of B12, although serum B12 levels were markedly increased. Reciprocally, intrathecal administration of B12 also caused only slight elevation of serum B12 as shown in Table 4 . A delay of more than four hours was seen before serum B12 level was elevated. B12 levels in the CSF is only 5-10% of the level found in serum (1) . Mean CSF B12 levels on 27 control subjects was 21 .2pg/ml, well in agreement with pre vious reports (8, 11, 12, 19) . Although significant correlation was demonstrated between serum and CSF B12 levels in the reports of WORM-PETERSEN (8) and SIMP SON (11) and BASIL et al. (12), we avoided observing the correlation between serum and CSF B12 levels in the present study because the microbiological assay is thought to be inadequate to have a good reproducibility at such a low concentration of B 12. The binding capacity of CSF protein has been examined by MEYER et al . (18) and WORM-PETERSEN (19) . According to them , the B12 binding capacity of CSF protein is higher than that of serum (18) and the nature of the protein is different from that in serum (19) . As a matter of fact, many reports claimed that CSF B 12 l evels were not significantly correlated with CSF protein levels , the present paper does not give any information on the relationship between CSF B12 and CSF protein. Further studies on CSF B12 and CSF protein are required.
RESULTS
No correlation between CSF Bit levels and neurological disorders was de monstrated. Changes of CSF B12 levels have been recorded in only two neuro logical diseases in literature. One is multiple sclerosis (elevation of CSF B 12) reported by SOBOTKA et al. (7), though not confirmed by others (8 , 11, 12) , and the other, pernicious anemia (low CSF B12) (8, 9, 13, 14) . In the present study, the CSF B12 level of a patient with pernicious anemia was 13pg/ml . This level is lower than the mean of the controls. Interestingly, the CSF B12 levels of patients with SMON were not significantly low . This finding confirms our previous conclu sion that B12 deficiency was not seen in patients with SMON (5) . Although UKYO (6) claimed that some disturbances were seen in the metabolism of B 12 in patients with SMON, it is rather difficult to assume such abnormalities by normal serum and CSF B12 levels in the patients with SMON .
The elevation of CSF B12 was demonstrated only in those patients receiv ing large amounts of B12 for a long time (Table 2 ) . There is very little infor mation concerning the transport of B12 from serum to CSF or vice versa . BASIL et al. (12) reported high CSF B12 (60-120pg/ml) in B12-treated multiple sclerosis .
As shown in Table 3 , a single injection of B12 failed to elevate CSF B 12 levels 1 and 3 days after the injection. But in rabbits , WORM-PETERSEN (15) observed rapid elevation of CSF B12 (4 times) after the injection of B12 into the ear vein , Further observation of CSF B12 levels shortly after the injection of B12 is required to explain the discrepancy between the present result in man and that in rabbit . Intrathecal administration of B12 elevated serum B12 levels but to very slight degrees and only after four hours. This result coincides with the report of UKYO (6) using 57CO-B12. The delay of the elevation of serum B 12 after the intrathecal injection of B12 suggests the presence of blood brain barrier for this vitamin con firming the report of BAUER et al. (16) . Although the number of observations are small both in the present study and others (6 , 15) , the existence of a selective control mechanism of the passage of B12 across the blood brain barrier is strongly suggested.
